Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 10/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.46 |
| ▸ | KDM5A | P29375 | 2/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16033536 | 0.89 | PHF8 (0.60) | PHF8KDM4CKDM2BVNN1GRM5 | |
| SCHEMBL16032963 | 0.85 | KDM4C (0.64) | PHF8KDM4CKDM2BKDM5AKDM5B | |
| SCHEMBL16034273 | 0.84 | KDM4C (0.69) | PHF8KDM4CKDM2B | |
| SCHEMBL16033927 | 0.80 | KDM4C (0.41) | PHF8KDM4CKDM2BKDM5AKDM5B | |
| SCHEMBL16035092 | 0.79 | PHF8 (0.67) | PHF8KDM4CKDM2BKDM5AKDM5B | |
| SCHEMBL16126232 | 0.78 | KDM4C (0.38) | PHF8KDM4CKDM2BGRM5KCNH2 | |
| SCHEMBL16034598 | 0.77 | KDM4C (0.41) | PHF8KDM4CKDM2BGRM5 | |
| SCHEMBL16033866 | 0.76 | KDM4C (0.69) | PHF8KDM4CKDM2B | |
| SCHEMBL16034004 | 0.76 | KDM4C (0.41) | PHF8KDM4CKDM2BGRM5 | |
| SCHEMBL16095836 | 0.75 | PHF8 (0.39) | PHF8KDM4CVNN1GRM5ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2969007-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2969007-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10273222-B2 | Histone demethylase inhibitors | CELGENE QUANTSCEL RESEARCH, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273222-B2 | Histone demethylase inhibitors | CELGENE QUANTSCEL RESEARCH, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| EP-2969007-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| WO-2014151945-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151945-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273222-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | PHF8 30/4885KDM4C 13/4885KDM2B 19/4885 |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | PHF8 30/4885KDM4C 13/4885KDM2B 19/4885 |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | PHF8 30/4885KDM4C 13/4885KDM2B 19/4885 |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | PHF8 30/4885KDM4C 13/4885KDM2B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.